Zobrazeno 1 - 10
of 57
pro vyhledávání: '"M L Fjällskog"'
Autor:
S. Aakko, A. Ylitalo, H. Kuusanmäki, M. Björkman, J. Mandelin, J. Jalkanen, M.-L. Fjällskog, C. Heckman, M. Hollmén, M. Kontro
Publikováno v:
HemaSphere, Vol 6, Pp 280-281 (2022)
Externí odkaz:
https://doaj.org/article/fefd2ecd79dd45dc99968176b37e44d5
Autor:
Markus Ringnér, Martin Lauss, Ingegerd Johansson, Ingrid Hedenfalk, M-L Fjällskog, Karolina Holm, Cecilia Nilsson
Publikováno v:
Cancer Research. 73:P1-17
Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all breast cancer cases. Although it is similar to female breast cancer (FBC) in many ways, distinct differences in incidence, age distribution, levels of hormone receptors, p
Autor:
Lisa Rydén, Marie Klintman, Mårten Fernö, Carina Strand, Signe Borgquist, P Malmtröm, Karin Jirström, Håkan Olsson, P-O Bendahl, Gunilla Chebil, Ingrid Hedenfalk, Olle Stål, A-K Falck, Martin Bak, M-L Fjällskog, Dorthe Grabau
Publikováno v:
Cancer Research. 72:P2-10
Purpose: The aim was to validate the prognostic value of a previously defined index (CAGE), combining proliferation (Cyclin A), histological grade, and estrogen receptor (ER) in different subsets of primary breast cancer patients. In the present stud
Autor:
RK Patel, VV Krol, Luis Samayoa, EA Pirruccello, AL Szabunio, PC McGrath, Michael L. Cibull, M-L Fjällskog
Publikováno v:
Cancer Research. 71:P3-07
Background Prognostic information and local control for managing the majority of clinically node (−) breast cancer patients may be achieved by sentinel node biopsy (SNB) alone and/or limited axillary dissections (LAD). Currently, 20 - 30% of clinic
Autor:
Eva Tiensuu Janson, M Grönberg, Ingrid Hedenfalk, Ingegerd Johansson, M-L Fjällskog, Cecilia Nilsson
Publikováno v:
Cancer Research. 71:P4-19
Background: Expression of the peptide hormones ghrelin and obestatin has previously been demonstrated in normal breast as well as in breast cancer. Interestingly, ghrelin expression has been shown to be associated with longer survival in female patie
Autor:
Leif Bergkvist, Ingegerd Johansson, R-M Amin, Marit Holmqvist, Cecilia Ahlin, Cecilia Nilsson, Ingrid Hedenfalk, M-L Fjällskog, S Thorstenson
Publikováno v:
Cancer Research. 71:P4-19
Purpose: To characterize male breast cancer (MBC) by evaluating established histopathological parameters and their prognostic value. Methods: 197 male patients with invasive breast cancer and available paraffin-embedded tumor tissue were retrospectiv
Autor:
Wenjing Zhou, Christer Johansson, R-M Amini, Karin Jirström, Fredrik Wärnberg, M-L Fjällskog, Carl Blomqvist, Anita Ringberg
Publikováno v:
Cancer Research. 71:P4-10
Background: The risk for recurrence after a primary ductal carcinoma in situ (DCIS) is approximately 8% after ten years. If a recurrence occurs, the risk of the recurrence being invasive is approximately 50%. However, the knowledge of determinants fo
Autor:
Pontus Berglund, Håkan Olsson, Åke Borg, Ingegerd Johansson, Johan Staaf, M-L Fjällskog, Göran Jönsson, Ingrid Hedenfalk, Lena Luts, Cecilia Nilsson, Markus Ringnér
Publikováno v:
Cancer Research. 70:P1-16
Background: Male breast cancer (MBC) is a rare disease, accounting for Results: Our data revealed a broad pattern of aberrations in MBC, confirming that MBC is a heterogeneous tumor type. Overall, MBC displayed more regions of genomic gain than FBC,
Autor:
Heli Nevanlinna, Päivi Heikkilä, Rose-Marie Amini, Cecilia Ahlin, Laura Salonen, Carl Blomqvist, Kirsimari Aaltonen, M-L Fjällskog
Publikováno v:
British Journal of Cancer
Cyclin A has in some studies been associated with poor breast cancer survival, although all studies have not confirmed this. Its prognostic significance in breast cancer needs evaluation in larger studies. Tissue microarray (TMA) technique allows a s
Autor:
Jonas Bergh, Rolf Larsson, Marie Sandström, Mats O. Karlsson, Agneta Freijs, Peter Nygren, M L Fjällskog
Publikováno v:
Journal of Clinical Oncology. 14:1581-1588
PURPOSE The aim of this study was to investigate the covariance between the pharmacokinetics of the three components of the FEC regimen, epirubicin (EPI), fluorouracil (5-FU), and the cyclophosphamide (CP) metabolite 4-hydroxycyclophosphamide (4-OHCP